June 9/2015
Finance
Latest Pharma M&A Trends: Frenzy and Risks Escalate
The pharma industry is making progress and going through a frenzy of activity on the strategic, business, M&A and financial fronts, writes Peter Young ... /Read more/ |
|
Europe
A Regulatory Dark Horse? Cross-Border Patients’ Rights in Europe
The European Union’s directive on patients’ rights in cross-border healthcare was seen as a bit of a damp squib when it was first adopted, but its importance is now coming into view, writes Reflector ... /Read more/ |
Emerging Markets
China’s Big Data Opportunity
Bryan Spielman outlines why China is poised for a data renaissance—one that could play a pivotal role in the next wave of pharma innovation ... /Read more/ |
Event
World Health Assembly Underlines Pharma's Global Challenges
Susan Crowley reviews the hotly debated agenda items from May’s World Health Assembly (WHA) in Geneva, Switzerland ... /Read more/ |
Event
ASCO (American Society of Clinical Oncology): Highlights of 2015 Annual Meeting
Casey McDonald presents some highlights from a blustery few days in Chicago, with immunotherapy and cost, predictably taking center stage ... /Read more/ |
industry update
• |
Apogenix (Heidelberg, Germany) appointed Peter Willinger as Chief Financial Officer. |
• |
Amgen (Zug, Switzerland) announced the appointment of Corinne Le Goff as Senior Vice President and Head of the European region. |
• |
Huntingdon Life Sciences and Harlan Laboratories (Huntingdon, UK) appointed Joseph Bedford, Ph.D., as Corporate Vice President of Global Strategic Marketing. |
• |
Nabriva Therapeutics (Vienna, Austria, and Philadelphia, PA) named Elyse Seltzer, MD, as Chief Medical Officer. Dr Seltzer assumes the role from Dr William Prince, who will transition to Senior Vice President, Clinical Science. |
|
|
|